In February 2021, the European Commission’s (“Commission”) long-running excessive pricing case against Aspen was brought to a close, with Aspen accepting a series of forward-looking pricing and supply commitments, but avoiding any fines or requirements to repay all of the higher prices charged (see VBB on Competition Law, Volume 2021, No. 2). This appears to have been a good result for Aspen, particularly in comparison with the € 5.2 million fine received in the 2016 decision from the Italian competition authority. Against this backdrop, it is
The EU Commission accepts the commitment offered by a pharmaceutical company for excessive pricing (Aspen)
Access to this article is restricted to subscribers
Already Subscribed? Sign-in
Access to this article is restricted to subscribers.
Read one article for free
Sign-up to read this article for free and discover our services.